ReviewMedicine2018

High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review.

Dandan Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.